UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical inflammatory activity associated with response to second-line treatments in multiple sclerosis

Journal of the neurological sciences, 2013-10, Vol.333, p.e409-e409

2013

Volltextzugriff (PDF)

MR Imaging Intensity Modeling of Damage and Repair In Multiple Sclerosis: Relationship of Short-Term Lesion Recovery to Progression and Disability

American journal of neuroradiology : AJNR, 2007-11, Vol.28 (10), p.1956-1963

2007

Volltextzugriff (PDF)

Medulla Oblongata Volume: A Biomarker of Spinal Cord Damage and Disability in Multiple Sclerosis

American journal of neuroradiology : AJNR, 2008-09, Vol.29 (8), p.1465-1470

2008

Volltextzugriff (PDF)

Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study

Journal of the neurological sciences, 2009-09, Vol.284 (1), p.116-119

2009

Volltextzugriff (PDF)

Induction of partial immune tolerance to factor VIII through prior mucosal exposure to the factor VIII C2 domain

Journal of thrombosis and haemostasis, 2006-10, Vol.4 (10), p.2172-2179

2006

Volltextzugriff (PDF)

Adverse event profile of alemtuzumab over time in treatment-naïve patients with early, active relapsing–/INS;remitting multiple sclerosis (RRMS; CARE-MS I study)

Journal of the neurological sciences, 2013-10, Vol.333, p.e374-e375

2013

Volltextzugriff (PDF)

Alemtuzumab improves visual outcomes in treatment-naïve patients with relapsing–/INS;remitting multiple sclerosis (RRMS): Analysis from the phase 3 CARE-MS I study

Journal of the neurological sciences, 2013-10, Vol.333, p.e375-e375

2013

Volltextzugriff (PDF)

Alemtuzumab treatment has no adverse impact on sperm quality, quantity, or motility: A CARE-MS substudy

Journal of the neurological sciences, 2013-10, Vol.333, p.e375-e376

2013

Volltextzugriff (PDF)

Regional White Matter Atrophy-Based Classification of Multiple Sclerosis in Cross-Sectional and Longitudinal Data

American journal of neuroradiology : AJNR, 2009-10, Vol.30 (9), p.1731-1739

2009

Volltextzugriff (PDF)

Demographic and clinical characteristics of malignant multiple sclerosis

Neurology, 2011-06, Vol.76 (23), p.1996-2001

2011

Volltextzugriff (PDF)

Antigen microarrays identify CNS-produced autoantibodies in RRMS

Neurology, 2012-02, Vol.78 (8), p.532-539

2012

Volltextzugriff (PDF)

CLA-supplemented diet accelerates experimental colorectal cancer by inducing TGF-β-producing macrophages and T cells

Mucosal immunology, 2019, Vol.12 (1), p.188-199

2019

Volltextzugriff (PDF)

The Impact of Lesion In-Painting and Registration Methods on Voxel-Based Morphometry in Detecting Regional Cerebral Gray Matter Atrophy in Multiple Sclerosis

American journal of neuroradiology : AJNR, 2012-09, Vol.33 (8), p.1579-1585

2012

Volltextzugriff (PDF)

Seasonal prevalence of MS disease activity

Neurology, 2010-08, Vol.75 (9), p.799-806

2010

Volltextzugriff (PDF)

HLA B44: protective effects in MS susceptibility and MRI outcome measures

Neurology, 2010-08, Vol.75 (7), p.634-640

2010

Volltextzugriff (PDF)

Brain MRI of nasal MOG therapeutic effect in relapsing-progressive EAE

Experimental neurology, 2014-05, Vol.255, p.63-70

2014

Volltextzugriff (PDF)

Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count

Multiple sclerosis and related disorders, 2018-02, Vol.20, p.51-57

2018

Volltextzugriff (PDF)

Disease steps in multiple sclerosis: a longitudinal study comparing Disease Steps and EDSS to evaluate disease progression

Multiple sclerosis, 1999-05, Vol.5 (5), p.349-354

1999

Volltextzugriff (PDF)

Clinical practice of immunosuppressive treatments in multiple sclerosis

Journal of the neurological sciences, 2004-08, Vol.223 (1), p.65-67

2004

Volltextzugriff (PDF)

HLA (A-B-C and -DRB1) alleles and brain MRI changes in multiple sclerosis: a longitudinal study

Genes and immunity, 2011-04, Vol.12 (3), p.183-190

2011

Volltextzugriff (PDF)

HLA

Genes and immunity, 2011-04, Vol.12 (3), p.183

2011

Volltextzugriff (PDF)

Cyclophosphamide Treatment of MS: Current Therapeutic Approaches and Treatment Regimens

International MS journal, 2010-03, Vol.17 (1), p.12

2010

Volltextzugriff (PDF)

Th2 and Th3 (TGF-beta) responses are associated with regulation of CNS autoimmunity in EAE and therapy of multiple sclerosis

Journal of neuroimmunology, 1998-09, Vol.90 (1), p.10-10

Weiner, H.L.

1998

Volltextzugriff (PDF)

Defective regulation of IFNγ and IL-12 by endogenous IL-10 in progressive MS

Neurology, 2000-07, Vol.55 (2), p.192-198

2000

Volltextzugriff (PDF)

Medulla Oblongata Volume: A Biomarker of Spinal Cord Damage and Disability in Multiple Sclerosis: Fig 1

American journal of neuroradiology : AJNR, 2008-09, Vol.29 (8), p.1465-1470

2008

Volltextzugriff (PDF)

1 – 25 von 71

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(58)

Publikationsform

Artikel
(64)
Buchkapitel
(7)

Sprache

Englisch
(71)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical inflammatory activity associated with response to second-line treatments in multiple sclerosis

MR Imaging Intensity Modeling of Damage and Repair In Multiple Sclerosis: Relationship of Short-Term Lesion Recovery to Progression and Disability

Medulla Oblongata Volume: A Biomarker of Spinal Cord Damage and Disability in Multiple Sclerosis

Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study

Induction of partial immune tolerance to factor VIII through prior mucosal exposure to the factor VIII C2 domain

Adverse event profile of alemtuzumab over time in treatment-naïve patients with early, active relapsing–/INS;remitting multiple sclerosis (RRMS; CARE-MS I study)

Alemtuzumab improves visual outcomes in treatment-naïve patients with relapsing–/INS;remitting multiple sclerosis (RRMS): Analysis from the phase 3 CARE-MS I study

Alemtuzumab treatment has no adverse impact on sperm quality, quantity, or motility: A CARE-MS substudy

Regional White Matter Atrophy-Based Classification of Multiple Sclerosis in Cross-Sectional and Longitudinal Data

Demographic and clinical characteristics of malignant multiple sclerosis

Antigen microarrays identify CNS-produced autoantibodies in RRMS

CLA-supplemented diet accelerates experimental colorectal cancer by inducing TGF-β-producing macrophages and T cells

The Impact of Lesion In-Painting and Registration Methods on Voxel-Based Morphometry in Detecting Regional Cerebral Gray Matter Atrophy in Multiple Sclerosis

Seasonal prevalence of MS disease activity

HLA B44: protective effects in MS susceptibility and MRI outcome measures

Brain MRI of nasal MOG therapeutic effect in relapsing-progressive EAE

Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count

Disease steps in multiple sclerosis: a longitudinal study comparing Disease Steps and EDSS to evaluate disease progression

Clinical practice of immunosuppressive treatments in multiple sclerosis

HLA (A-B-C and -DRB1) alleles and brain MRI changes in multiple sclerosis: a longitudinal study

HLA

Cyclophosphamide Treatment of MS: Current Therapeutic Approaches and Treatment Regimens

Th2 and Th3 (TGF-beta) responses are associated with regulation of CNS autoimmunity in EAE and therapy of multiple sclerosis

Defective regulation of IFNγ and IL-12 by endogenous IL-10 in progressive MS

Medulla Oblongata Volume: A Biomarker of Spinal Cord Damage and Disability in Multiple Sclerosis: Fig 1

Suchergebnisse filtern